

HAEMONETICS CORP  
Form 10-Q  
February 03, 2009  
[Table of Contents](#)

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549



# FORM 10-Q

## Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarter ended: December 27, 2008 Commission File Number: 1-10730

## HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction  
of incorporation or organization)

**04-2882273**  
(I.R.S. Employer Identification No.)

**400 Wood Road, Braintree, MA 02184**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(781) 848-7100**

Indicate by check mark whether the registrant (1.) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) (2.) has been subject to the filing requirements for at least the past 90 days.

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Edgar Filing: HAEMONETICS CORP - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes  No

The number of shares of \$.01 par value common stock outstanding as of December 27, 2008:

25,431,571

---

Table of Contents

**HAEMONETICS CORPORATION**

**INDEX**

	<b>PAGE</b>
<b>PART I. FINANCIAL INFORMATION</b>	
<b><u>ITEM 1. Financial Statements</u></b>	
<u>Unaudited Consolidated Statements of Income - Three and Nine Months Ended December 27, 2008 and December 29, 2007</u>	2
<u>Unaudited Consolidated Balance Sheets - December 27, 2008 and March 29, 2008</u>	3
<u>Unaudited Consolidated Statement of Stockholders - Equity - Nine Months Ended December 27, 2008</u>	4
<u>Unaudited Consolidated Statements of Cash Flows - Nine Months Ended December 27, 2008 and December 29, 2007</u>	5
Notes to Unaudited Consolidated Financial Statements	6
<b><u>ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	25
<b><u>ITEM 3. Quantitative and Qualitative Disclosures about Market Risk</u></b>	40
<b><u>ITEM 4. Controls and Procedures</u></b>	41
<b><u>PART II. OTHER INFORMATION</u></b>	42
<b><u>ITEM 6. Exhibits</u></b>	42
<u>Signatures</u>	43

Table of Contents

## ITEM 1. FINANCIAL STATEMENTS

## HAEMONETICS CORPORATION AND SUBSIDIARIES

## CONSOLIDATED STATEMENTS OF INCOME

(Unaudited in thousands, except per share data)

	Three months ended		Nine months ended	
	December 27 2008	December 29 2007	December 27 2008	December 29 2007
Net revenues	\$ 155,447	\$ 134,587	\$ 445,482	\$ 377,701
Cost of goods sold	77,151	68,029	219,460	189,761
<b>Gross profit</b>	<b>78,296</b>	<b>66,558</b>	<b>226,022</b>	<b>187,940</b>
Operating expenses:				
Research and development	5,840	5,529	16,901	18,532
Selling, general and administrative	47,965	41,432	141,687	119,418
<b>Total operating expenses</b>	<b>53,805</b>	<b>46,961</b>	<b>158,588</b>	<b>137,950</b>
Operating income	24,491	19,597	67,434	49,990
Interest income, net	449	1,070	1,569	4,037
Other (expense)/income, net	(1,451)	225	(2,366)	1,905
Income before provision for income taxes	23,489	20,892	66,637	55,932
Provision for income taxes	7,273	6,538	21,272	17,733
<b>Net income</b>	<b>\$ 16,216</b>	<b>\$ 14,354</b>	<b>\$ 45,365</b>	<b>\$ 38,199</b>
<b>Basic income per common share</b>				
Net income	\$ 0.64	\$ 0.56	\$ 1.79	\$ 1.48
<b>Income per common share assuming dilution</b>				
Net income	\$ 0.62	\$ 0.54	\$ 1.73	\$ 1.43
<b>Weighted average shares outstanding</b>				
Basic	25,375	25,500	25,340	25,881
Diluted	26,056	26,437	26,163	26,776

The accompanying notes are an integral part of these consolidated financial statements





Table of Contents**HAEMONETICS CORPORATION AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

(in thousands)

	December 27, 2008 (Unaudited)	March 29, 2008
<b>ASSETS</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 125,325	\$ 133,553
Accounts receivable, less allowance of \$1,994 at December 27, 2008 and \$2,365 at March 29, 2008	124,575	120,252
Inventories, net	73,557	65,388
Deferred tax asset, net	8,491	12,058
Prepaid expenses and other current assets	21,944	28,183
<b>Total current assets</b>	<b>353,892</b>	<b>359,434</b>
<b>Property, plant and equipment:</b>		
Land, building and building improvements	42,487	43,873
Plant equipment and machinery	101,232	88,811
Office equipment and information technology	52,844	52,787
Haemonetics equipment	189,531	178,827
Total property, plant and equipment	386,094	364,298
Less: accumulated depreciation	(256,624)	(247,814)
<b>Net property, plant and equipment</b>	<b>129,470</b>	<b>116,484</b>
<b>Other assets:</b>		
Other intangibles, less amortization of \$24,078 at December 27, 2008 and \$19,821 at March 29, 2008	63,936	64,333
Goodwill	55,434	54,222
Deferred tax asset, long term	14,784	9,244
Other long-term assets	4,832	5,233
<b>Total other assets</b>	<b>138,986</b>	<b>133,032</b>
<b>Total assets</b>	<b>\$ 622,348</b>	<b>\$ 608,950</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
<b>Current liabilities:</b>		
Notes payable and current maturities of long-term debt	\$ 4,434	\$ 6,326
Accounts payable	17,201	19,724
Accrued payroll and related costs	24,967	19,824
Accrued income taxes	6,466	5,285
Other liabilities	32,466	46,518
<b>Total current liabilities</b>	<b>85,534</b>	<b>97,677</b>
Long-term debt, net of current maturities	5,522	6,037
Long-term deferred tax liability	7,655	3,253
Other long-term liabilities	7,849	7,795
Commitments and contingencies (Note 13)		
<b>Stockholders equity:</b>		
Common stock, \$0.01 par value; Authorized - 150,000,000 shares; Issued and outstanding 25,431,571 shares at December 27, 2008 and 25,694,769 shares at March 29, 2008	254	256
Additional paid-in capital	217,036	186,933

Edgar Filing: HAEMONETICS CORP - Form 10-Q

Retained earnings		295,576		302,196
Accumulated other comprehensive income		2,922		4,803
Total Stockholders equity		515,788		494,188
<b>Total liabilities and stockholders equity</b>	\$	622,348	\$	608,950

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

**HAEMONETICS CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY AND OTHER COMPREHENSIVE INCOME**  
**(Unaudited in thousands)**

	Common Stock		Additional		Retained	Accumulated Other	Total	Comprehensive			
	Shares	\$	s	Paid-in	Earnings	Comprehensive	Stockholders	Income			
				Capital		Income / (Loss)	Equity				
<b>Balance, March 29, 2008</b>	25,695	\$	256	\$	186,933	\$	302,196	\$	4,803	\$	494,188
Employee stock purchase plan	59		1		2,658						2,659
Exercise of stock options and related tax benefit	760		8		28,141						28,149
Shares repurchased	(1,100)		(11)		(8,003)		(51,984)				(59,998)
Issuance of restricted stock, net of cancellations	18										
Stock Compensation expense					7,307						7,307
Net income											45,365
Foreign currency translation adjustment										(7,983)	(7,983)
Unrealized gain on hedges, net										1,833	1,833
Reclassification of hedge loss to earnings										4,269	4,269
Comprehensive income											43,484
<b>Balance, December 27, 2008</b>	25,432	\$	254	\$	217,036	\$	295,576	\$	2,922	\$	515,788

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

**HAEMONETICS CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited in thousands)

	Nine Months Ended	
	December 27, 2008	December 29, 2007
<b>Cash Flows from Operating Activities:</b>		
Net income	\$ 45,365	\$ 38,199
<b>Adjustments to reconcile net income to net cash provided by operating activities:</b>		
<b>Non cash items:</b>		
Depreciation and amortization	29,841	22,398
Stock compensation expense	7,307	7,122
Loss/(gain) on sales of plant, property and equipment	142	(739)
Unrealized loss/(gain) from hedging activities	2,333	(1,582)
<b>Change in operating assets and liabilities:</b>		
Increase in accounts receivable, net	(7,936)	(13,377)
Increase in inventories	(8,920)	(2,559)
(Increase)/Decrease in prepaid income taxes	(1,316)	651
Increase in other assets and other long-term liabilities	(3,763)	(9,165)
Tax benefit of exercise of stock options	2,688	1,671
Increase in accounts payable and accrued expenses	6,917	3,171
Net cash provided by operating activities	72,658	45,790
<b>Cash Flows from Investing Activities:</b>		
Capital expenditures on property, plant and equipment	(45,670)	(42,497)
Proceeds from sale of property, plant and equipment	2,522	3,149
Acquisition of Medicell	(2,459)	
Acquisition of HaemoScope		(45,080)
Acquisition of Infonale, Inc.		(1,300)
Net cash used in investing activities	(45,607)	(85,728)
<b>Cash Flows from Financing Activities:</b>		
Payments on long-term real estate mortgage	(515)	(473)
Net decrease in short-term revolving credit agreements	(2,431)	(10,651)
Payments on long-term credit agreements		(5,714)
Employee stock purchase plan	2,659	2,209
Exercise of stock options	20,299	14,896
Excess tax benefit on exercise of stock options	6,106	1,274
Stock Repurchase	(59,998)	(74,996)
Net cash used in financing activities	(33,880)	(73,455)
Effect of Exchange Rates on Cash and Cash Equivalents	(1,399)	1,023
<b>Net Decrease in Cash and Cash Equivalents</b>	<b>(8,228)</b>	<b>(112,370)</b>
<b>Cash and Cash Equivalents at Beginning of Year</b>	<b>133,553</b>	<b>229,227</b>
<b>Cash and Cash Equivalents at End of Period</b>	<b>\$ 125,325</b>	<b>\$ 116,857</b>
<b>Non-cash Investing and Financing Activities:</b>		
Transfers from inventory to fixed assets for placements of Haemonetics equipment	\$ 6,174	\$ 1,672
<b>Supplemental Disclosures of Cash Flow Information:</b>		
Interest paid	\$ 414	\$ 849
Income taxes paid	\$ 19,951	\$ 22,544

Edgar Filing: HAEMONETICS CORP - Form 10-Q

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

**1. BASIS OF PRESENTATION**

Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles ( GAAP ) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All significant intercompany transactions have been eliminated. Certain reclassifications were made to prior year balances to conform with the presentation of the financial statements as of and for the three and nine month periods ended December 27, 2008. Operating results for the three and nine month periods ended December 27, 2008 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 28, 2009, or any other interim period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended March 29, 2008.

Our fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2009 and 2008 include 52 weeks with all four quarters including 13 weeks.

***Revenue Recognition***

Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with SAB No. 104, Revenue Recognition , EITF 00-21, Revenue Arrangements with Multiple Deliverables and Statement of Position ( SOP ) 97-2, Software Revenue Recognition, as amended . These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured. When more than one element such as equipment, disposables and services are contained in a single arrangement, we allocate revenue between the elements based on each element 's relative fair value, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand alone basis and there is objective and reliable evidence of the fair value of the undelivered items. The fair value of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by using other objective evidence as defined in EITF 00-21, or vendor specific objective evidenced under SOP 97-2.

***Product Revenues***

**Product sales consist of the sale of our equipment devices and the related disposables used with these devices. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. Examples of common post delivery obligations are installation and training. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor 's location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. All shipments to distributors are at contract prices and payment is not contingent upon resale of the product.**



Table of Contents

*Software and Service Revenues*

At this time, our software and services business principally provides support to our plasma and blood collection customers. Through our Software Solutions Division, (formerly 5D Information Management and Information Data Management), we provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities. Software license revenues are generally billed periodically, monthly or quarterly and recognized over the period in which the service is provided. Our software and service business model includes the provision of services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.

**2. RECENT ACCOUNTING PRONOUNCEMENTS**

In September 2008, the FASB issued FASB Staff Position (FSP) No. 133-1 and FIN 45-4, Disclosures about Credit Derivatives and Certain Guarantees: An Amendment of FASB Statement No. 133 and FASB Interpretation No. 45. The FSP is intended to improve disclosures about credit derivatives by requiring more information about the potential adverse effects of changes in credit risk on the financial position, financial performance, and cash flows of the sellers of credit derivatives. It amends FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities, to require disclosures by sellers of credit derivatives, including credit derivatives embedded in hybrid instruments. The provisions of the FSP that amend Statement 133 and Interpretation 45 are effective for reporting periods (annual or interim) ending after November 15, 2008. These statements became effective during this quarter and did not have an impact on our financial position and results of operation as we have not issued or purchased credit derivatives.

In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally Accepted Accounting Principles, which will provide framework for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (GAAP) for nongovernmental entities. Prior to the issuance of SFAS No. 162, the GAAP hierarchy was defined in the American Institute of Certified Public Accountants (AICPA) Statement on Auditing Standards (SAS) No. 69, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles. With the issuance of SFAS No. 162, the GAAP hierarchy for nongovernmental entities will move from auditing literature to accounting literature. SFAS No. 162 will be effective 60 days following the SEC's approval of the Public Company Accounting Oversight Board (PCAOB) amendments to AU Section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles. This statement became effective during this quarter and did not have an impact on our financial position and results of operations.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities, as an amendment of SFAS No. 133. SFAS No. 161 is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity's financial position, financial performance, and cash flows. SFAS No. 161 is effective for any reporting period (annual or quarterly interim) beginning on or after November 15, 2008. We are currently evaluating the potential impact of SFAS No. 161 on our financial position and results of operations. This statement is effective for our fourth quarter interim period ending March 28, 2009 and our 2009 annual financial statements.



## Edgar Filing: HAEMONETICS CORP - Form 10-Q

In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations ( SFAS 141(R) ). In SFAS 141(R), the FASB retained the fundamental requirements of SFAS No. 141 to account for all business combinations using the acquisition method (formerly the purchase method) and for an acquiring entity to be identified in all business combinations. However, the new standard requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction; establishes

Table of Contents

the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors and other users all of the information they need to evaluate and understand the nature and financial effect of the business combination. SFAS 141(R) is effective for annual periods beginning on or after December 15, 2008. We are currently evaluating the potential impact of SFAS 141(R) on our financial position and results of operations. This statement is effective for our fiscal year 2010.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements - an amendment of ARB No. 51, of which the objective is to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards by requiring all entities to report noncontrolling (minority) interests in subsidiaries in the same way - as equity in the consolidated financial statements. Moreover, SFAS No. 160 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. SFAS No. 160 is effective for annual periods beginning on or after December 15, 2008. We are currently evaluating the potential impact of SFAS No. 160 on our financial position and results of operations. This statement is effective for our fiscal year 2010.

**3. EARNINGS PER SHARE ( EPS )**

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations, as required by SFAS Statement No. 128, Earnings Per Share. Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares.

Table of Contents

	For the Three Months Ended	
	December 27, 2008	December 29, 2007
(in thousands, except per share amounts)		
<b>Basic EPS</b>		
Net income	\$ 16,216	\$ 14,354
Weighted average shares	25,375	25,500
Basic income per share	\$ 0.64	\$ 0.56
<b>Diluted EPS</b>		
Net income	\$ 16,216	\$ 14,354
Basic weighted average shares	25,375	25,500
Dilutive effect of stock options and restricted stock units	681	937
Diluted weighted average shares	26,056	26,437
Diluted income per share	\$ 0.62	\$ 0.54

	For the Nine Months Ended	
	December 27, 2008	December 29, 2007
(in thousands, except per share amounts)		
<b>Basic EPS</b>		
Net income	\$ 45,365	\$ 38,199
Weighted average shares	25,340	25,881
Basic income per share	\$ 1.79	\$ 1.48
<b>Diluted EPS</b>		
Net income	\$ 45,365	\$ 38,199
Basic weighted average shares	25,340	25,881
Dilutive effect of stock options and restricted stock units	823	895
Diluted weighted average shares	26,163	26,776
Diluted income per share	\$ 1.73	\$ 1.43

**4. STOCK-BASED COMPENSATION**

Stock-based compensation expense of \$7.3 million and \$7.1 million was recognized for the nine months ended December 27, 2008 and December 29, 2007, respectively. The related income tax benefit recognized in the consolidated statements of income was \$2.1 million for both the nine month periods ended December 27, 2008 and December 29, 2007. We recognize stock-based compensation on a straight line basis.

Table of Contents

For a more detailed description of our stock-based compensation plans, see Note 11 Capital Stock to the Company's consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 29, 2008. Our stock-based compensation plans currently consist of stock options, restricted stock awards, restricted stock units and an employee stock purchase plan. Options become exercisable in the manner specified by the Compensation Committee of our Board of Directors. With the exception of one performance based restricted stock award granted in the first quarter of this year and an option award with a five year vesting period granted in the third quarter of this year, all options, restricted stock awards and restricted stock units granted to employees in the nine months ended December 27, 2008 vest over a four year period of time and the options expire not more than 7 years from the date of grant.

Cash flows relating to the benefits of tax deductions in excess of compensation cost recognized (in our reported results) are reported as a financing cash flow, rather than as an operating cash flow and are recognized as a credit to additional paid-in-capital. This excess tax benefit was \$0.7 million and \$0.5 million for the three months ended December 27, 2008 and December 29, 2007, respectively, and \$6.1 million and \$1.3 million for the nine months ended December 27, 2008 and December 29, 2007, respectively.

A summary of information related to stock options is as follows:

	Options Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value (\$ 000 s)
Outstanding at March 29, 2008	3,657,566	\$ 37.05	4.61	\$ 79,183
Granted	842	\$ 57.86		
Exercised	(180,095)	\$ 26.52		
Forfeited	(40,030)	\$ 45.80		
Outstanding at June 28, 2008	3,438,283	\$ 37.51	4.37	\$ 69,606
Granted	46,138	\$ 58.45		
Exercised	(480,045)	\$ 26.69		
Forfeited	(10,589)	\$ 39.65		
Outstanding at September 27, 2008	2,993,787	\$ 39.55	4.35	\$ 63,933
Granted	363,939	\$ 54.30		
Exercised	(99,365)	\$ 27.16		
Forfeited	(22,505)	\$ 49.03		
Outstanding at December 27, 2008	3,235,856	\$ 41.53	4.44	\$ 44,426
Exercisable at December 27, 2008	2,087,991	\$ 36.20	3.89	\$ 39,696
Expected to Vest at December 27, 2008	2,985,496	\$ 40.75	4.37	\$ 43,306

The total intrinsic value of options exercised during the three month periods ended December 27, 2008 and December 29, 2007, was \$2.8 million and \$5.8 million, respectively. The total intrinsic value of options exercised was \$21.6 million and \$16.4 million for the nine month periods ended December 27, 2008 and December 29, 2007, respectively.

Edgar Filing: HAEMONETICS CORP - Form 10-Q

As of December 27, 2008 and December 29, 2007, there was \$13.8 million and \$16.2 million, respectively, of total unrecognized compensation cost related to non vested stock options. That cost is expected to be recognized over a weighted average period of 2.4 years and 2.3 years, respectively. The total fair value of shares fully vested during the nine months ended December 27, 2008 and December 29, 2007 was \$29.0 million \$34.0 million, respectively.

Table of Contents

The weighted average fair value for our options granted in the first nine months of fiscal year 2009 and 2008 was \$16.67 and \$17.45, respectively. The fair value was estimated using the Black-Scholes option-pricing model based on the weighted average of the high and low stock prices at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of our common stock. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period. The assumptions utilized for option grants during the periods presented are as follows:

	Nine Months Ended	
	December 27, 2008	December 29, 2007
Stock Options Black-Scholes assumptions (weighted average):		
Volatility	29.79%	29.56%
Expected life (years)	4.9	5.0
Risk-free interest rate	2.69%	4.07%
Dividend yield	0.00%	0.00%

As of December 27, 2008 and December 29, 2007, there was \$0.3 and \$0.3 million, respectively, of total unrecognized compensation cost related to non vested restricted stock awards. That cost was expected to be recognized over a weighted average period of 1.92 and 3.34 years, respectively. The total fair value of restricted stock awards vested during the nine months ended December 27, 2008 was \$0.1 million and \$0.0 million during the nine months ended December 29, 2007.

A summary of information related to restricted stock awards is as follows:

	Shares	Weighted Average Grant Date Fair Value
Nonvested at March 29, 2008	10,000	\$ 48.09
Granted	3,456	\$ 57.22
Released	(2,500)	\$ 48.09
Forfeited		
Terminated		
Nonvested at December 27, 2008	10,956	\$ 50.97

As of December 27, 2008 and December 29, 2007, there was \$4.2 and \$2.2 million, respectively, of total unrecognized compensation cost related to non vested restricted stock units. That cost was expected to be recognized over a weighted average period of 3.4 and 3.7 years, respectively. The total fair value of shares fully vested was \$0.8 million and \$0.0 million for the nine months ended December 27, 2008 and December 29, 2007, respectively.

A summary of information related to restricted stock units is as follows:



Table of Contents

	Shares		Weighted Average Market Value at Grant Date
Nonvested at March 29, 2008	58,332	\$	51.52
Granted	210	\$	57.23
Vested			
Forfeited	(1,905)	\$	50.90
Nonvested at June 28, 2008	56,637	\$	51.56
Granted	5,591	\$	58.19
Vested	(2,225)	\$	50.23
Forfeited	(937)	\$	51.33
Nonvested at September 27, 2008	59,066	\$	52.24
Granted	56,237	\$	54.48
Vested	(12,417)	\$	51.33
Forfeited	(1,361)	\$	51.33
Nonvested at December 27, 2008	101,525	\$	53.61

As of December 27, 2008 and December 29, 2007, there was \$0.3 and \$0.1 million, respectively, of total unrecognized compensation expense, net of estimated forfeitures, related to the Employee Stock Purchase Plan ( ESPP ) shares. That cost was expected to be recognized over the remainder of fiscal year 2009 and fiscal year 2008, respectively.

During the nine months ended December 27, 2008 and December 29, 2007, there were 59,263 and 55,766 shares purchased under the ESPP, respectively. They were purchased at \$44.86 and \$39.61 per share under the ESPP.

## 5. ACCOUNTING FOR SHIPPING AND HANDLING COSTS

Shipping and handling costs are included in cost of goods sold with the exception of \$5.0 million and \$2.8 million for the three months ended December 27, 2008 and December 29, 2007, respectively, and \$10.8 million and \$7.2 million for the nine months ended December 27, 2008 and December 29, 2007, respectively, that are included in selling, general, and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.

## 6. FOREIGN CURRENCY



## Edgar Filing: HAEMONETICS CORP - Form 10-Q

We enter into forward exchange contracts to hedge the probable cash flows from forecasted inter-company foreign currency denominated revenues, principally Japanese Yen and Euro. The purpose of our hedging strategy is to lock in foreign exchange rates for 12 months to minimize, for this period of time, the unforeseen impact on our results of operations of fluctuations in foreign exchange rates. We also enter into forward contracts that settle within 35 days to hedge certain monetary assets and liabilities denominated in foreign currencies. These derivative financial instruments are not used for trading purposes. The forward exchange contracts are recorded at

Table of Contents

fair value and are included in other current assets or other current liabilities on our consolidated balance sheets. The gains or losses on the forward exchange contracts designated as hedges are recorded in net revenues on our consolidated statements of income when the underlying hedge transaction affects earnings. The cash flows related to the gains and losses on these foreign currency hedges are classified in the consolidated statements of cash flows as part of cash flows from operating activities. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company would reclassify any gain or loss on the related cash flow hedge from other comprehensive income to earnings at that time. The ineffective portion of a derivative's change in fair value is recognized currently in other income, net in our consolidated statements of income.

**7. PRODUCT WARRANTIES**

We provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.

	<b>For the three months ended</b>	
	<b>December 27, 2008</b>	<b>December 29, 2007</b>
	<b>(in thousands)</b>	
Warranty accrual as of the beginning of the period	\$ 992	\$ 734
Warranty Provision	620	431
Warranty Spending	(436)	(431)
Warranty accrual as of the end of the period	\$ 1,176	\$ 734

	<b>For the nine months ended</b>	
	<b>December 27, 2008</b>	<b>December 29, 2007</b>
	<b>(in thousands)</b>	
Warranty accrual as of the beginning of the period	\$ 929	\$ 734
Warranty Provision	1,496	1,420
Warranty Spending	(1,249)	(1,420)
Warranty accrual as of the end of the period	\$ 1,176	\$ 734

**8. COMPREHENSIVE INCOME**

Comprehensive income is the total of net income and all other non-owner changes in stockholders' equity. For us, all other non-owner changes are primarily foreign currency translation, the change in our net minimum pension liability, and the changes in fair value of the effective portion of our outstanding cash flow hedge contracts.

A summary of the components of other comprehensive income is as follows:

Table of Contents

(In thousands)	For the three months ended	
	December 27, 2008	December 29, 2007
Net income	\$ 16,216	\$ 14,354
Other comprehensive income:		
Foreign currency translation	(2,328)	1,479
Unrealized gain/(loss) on cash flow hedges, net of tax	(2,857)	(1,277)
Reclassifications into earnings of cash flow hedge losses, net of tax	331	1,098
Total comprehensive income	\$ 11,362	\$ 15,654

(In thousands)	For the nine months ended	
	December 27, 2008	December 29, 2007
Net income	\$ 45,365	\$ 38,199
Other comprehensive income:		
Foreign currency translation	(7,983)	5,251
Unrealized gain/(loss) on cash flow hedges, net of tax	1,833	(3,207)
Reclassifications into earnings of cash flow hedge losses, net of tax	4,269	1,544
Total comprehensive income	\$ 43,484	\$ 41,787

**9. INVENTORIES**

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.

Inventories consist of the following:

	December 27, 2008	March 29, 2008
	(in thousands)	
Raw materials	\$ 22,857	\$ 16,107
Work-in-process	10,727	14,430
Finished goods	39,973	34,851
	\$ 73,557	\$ 65,388

**10. GOODWILL AND OTHER INTANGIBLE ASSETS****Goodwill**

The change in the carrying amount of our goodwill during the nine months ended December 27, 2008 is as follows (in thousands):

Table of Contents

Carrying amount as of March 29, 2008	\$	54,222
Medicell (a)		1,020
Haemoscope (b)		22
Effect of change in rates used for translation		170
Carrying amount as of December 27, 2008	\$	55,434

---

(a) A full description of the acquisition of Medicell Ltd., which occurred on April 4, 2008, is included in Foot Note #10, Goodwill and Other Intangibles, of our Form 10-Q for the quarter ended June 28, 2008.

(b) See Foot Note #3, Acquisitions, in our fiscal year 2008 Form 10-K for a full description of the acquisition of Haemoscope Corporation's TEG® Thrombelastograph® Hemostasis Analyzer business, which occurred on November 20, 2007.

Table of Contents**Other Intangible Assets****As of December 27, 2008**

	Gross Carrying Amount (in thousands)	Accumulated Amortization (in thousands)	Weighted Average Useful Life (in years)
Amortized Intangibles			
Patents	\$ 11,926	\$ 4,742	11
Capitalized Software	15,382	301	5
Other technology	29,682	11,315	10
Customer contracts and related relationships	29,925	7,561	12
Trade Names	1,099	159	7
Subtotal	\$ 88,014	\$ 24,078	14

**As of March 29, 2008**

	Gross Carrying Amount (in thousands)	Accumulated Amortization (in thousands)	Weighted Average Useful Life (in years)
Amortized Intangibles			
Patents	\$ 11,725	\$ 4,073	12
Capitalized Software	13,638	296	6
Other technology	28,327	10,013	11
Customer contracts and related relationships	29,342	5,439	8
Trade Names	600	0	12
Subtotal	83,632	19,821	11
Indefinite Life Intangibles Trade name	522	n/a	Indefinite
Total Intangibles	\$ 84,154	\$ 19,821	

The changes to the net carrying value of our intangible assets from March 29, 2008 to December 27, 2008, reflect the capitalization of software costs associated with our devices and software products (see Footnote #17), amortization expense and the effect of exchange rate changes in the translation of our intangible assets held by our international subsidiaries.



For the three months ended December 27, 2008 and December 29, 2007, amortization expense for amortized other intangible assets was \$1.4 million and \$0.9 million, respectively. For the nine months ended December 27, 2008 and December 29, 2007, amortization expense for amortized other intangible assets was \$4.4 million and \$2.6 million, respectively. Annual amortization expense is expected to approximate \$5.8 million for fiscal year

Table of Contents

2009, \$6.8 million for fiscal year 2010, \$6.7 million for fiscal year 2011, \$6.2 million for fiscal year 2012, \$6.1 million for fiscal year 2013, and \$6.7 million for fiscal year 2014.

**11. FAIR VALUE MEASUREMENT**

We adopted Financial Accounting Standards Board (FASB) Statement No. 157, *Fair Value Measurements*, as of March 30, 2008. Statement No. 157 defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Statement No. 157 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In February 2008, the FASB released Staff Position No. 157-2, *Effective Date of FASB Statement No. 157*, which delays the effective date of Statement No. 157 for all nonfinancial assets and nonfinancial liabilities, except for those that are recognized or disclosed at fair value in the financial statements on a recurring basis. In accordance with Staff Position No. 157-2, we have not applied the provisions of Statement No. 157 to the following nonfinancial assets and nonfinancial liabilities:

- Nonfinancial assets and nonfinancial liabilities initially measured at fair value in a business combination or other new basis event, but not measured at fair value in subsequent reporting periods;
- Reporting units and nonfinancial assets and nonfinancial liabilities measured at fair value for our goodwill impairment test in accordance with FASB Statement No. 142, *Goodwill and Other Intangible Assets*;
- Indefinite-lived intangible assets measured at fair value for impairment assessment in accordance with Statement No. 142;
- Nonfinancial long-lived assets or asset groups measured at fair value for impairment assessment or disposal under FASB Statement No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets*; and
- Nonfinancial liabilities associated with exit or disposal activities initially measured at fair value under FASB Statement No. 146, *Accounting for Costs Associated with Exit or Disposal Activities*.

We will be required to apply the provisions of Statement No. 157 to these nonfinancial assets and nonfinancial liabilities as of March 29, 2009 and are currently evaluating the impact of the application of Statement No. 157 as it pertains to these items. The application of Statement No. 157 for financial assets and financial liabilities did not have a material impact on our financial position, results of operations or cash flows.

On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds and foreign currency derivative contracts. Statement No. 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.

## Edgar Filing: HAEMONETICS CORP - Form 10-Q

Statement No. 157 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:

- Level 1 Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
- Level 2 Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

Table of Contents

- **Level 3** Inputs to the valuation methodology are unobservable inputs based on management's best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are generally classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB Statement No. 133, *Accounting for Derivative Instruments and Hedging Activities*. We determine the fair value of these instruments using the framework prescribed by Statement No. 157 by considering the estimated amount we would receive or pay to terminate these agreements at the reporting date and by taking into account current interest rates, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. We use a discounted cash flow model to value these forward foreign exchange contracts. The most significant input to this model is the current foreign exchange spot rate. We have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy because these observable inputs are available for substantially the full term of our derivative instruments.

*Fair Value Measured on a Recurring Basis*

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of December 27, 2008:

(in thousands)	Quoted Market Prices for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total
<b><u>Assets</u></b>				
Money market funds	\$ 89,043	\$	\$	\$ 89,043
Forward currency exchange contracts	\$ 89,043	\$ 3,300	\$	\$ 92,343
<b><u>Liabilities</u></b>				
Forward currency exchange contracts	\$	\$ 5,847	\$	\$ 5,847
	\$	\$ 5,847	\$	\$ 5,847

There were no assets or liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended December 27, 2008.

*Statement No. 159*

## Edgar Filing: HAEMONETICS CORP - Form 10-Q

In February 2007, the FASB issued Statement No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities, including an amendment of FASB Statement No. 115*, which allows an entity to elect to record financial assets and financial liabilities at fair value upon their initial recognition on a contract-by-contract basis. We adopted Statement No. 159 as of March 30, 2008 and did not elect the fair value option for our eligible financial assets and financial liabilities.

Table of Contents**12. INCOME TAXES**

Our reported tax rate includes two principal components: an annual effective tax rate and discrete items that are recorded in the quarter that an event occurs. Events or items that give rise to discrete recognition include finalizing audit examinations for open tax years and a statute of limitations expiration.

	For the three months ended		For the nine months ended	
	December 27, 2008	December 29, 2007	December 27, 2008	December 29, 2007
Annual Effective Tax Rate	35.1%	35.9%	35.1%	35.0%
Discrete Items	(4.1)%	(4.6)%	(3.2)%	(3.3)%
Reported Income Tax Rate	31.0%	31.3%	31.9%	31.7%

The annual effective rate for the three months ended December 27, 2008 was 35.1%, a decrease of 0.8% over the three months ended December 29, 2007. This decrease is a result of changes in the global distribution of our income, partially offset by a reduction in tax exempt income. The annual effective rate for the nine months ended December 27, 2008 was 35.1%, an increase of 0.1% over that for the nine months ended December 29, 2007. This increase is a result of a reduction in tax exempt income, partially offset by a change in the global distribution of our income.

Discrete tax benefits were recognized in the three months ended December 27, 2008 and December 29, 2007. For the third quarter of fiscal 2009, the discrete benefits totaled \$973,000. The noted discrete benefits were comprised of the release of \$1.1 million tax reserves due to a statute of limitations expiration and a \$135,000 discrete benefit for the reinstated research & development credit for the first and second quarter of fiscal 2009 that was offset in part by a \$301,000 tax provision due to the finalization of our fiscal 2008 U.S. Federal income tax returns. For the nine months ended December 27, 2008 discrete tax benefits totaled \$2.1 million, including the amounts described above, and benefits of \$1.2 million related to a statute of limitations expiration in Japan.

Future adjustments may increase or decrease the reported tax rate.

As of March 29, 2008, our unrecognized tax benefits totaled approximately \$5.2 million which, if recognized, would favorably affect our effective tax rate in future periods. Each year the statute of limitations for income tax returns filed in various jurisdictions closes, sometimes without adjustments. In the nine months ended December 27, 2008, there was a release of \$2.0 million of tax reserves as a result of the expiration of the statute of limitations. Total unrecognized tax benefits on December 27, 2008 were \$3.2 million. At this time, we do not expect any further release of tax reserves in fiscal 2009.

Our historic practice has been and continues to be to recognize interest and penalties related to federal, state, and foreign income tax matters in income tax expense. Approximately \$0.9 million and \$0.8 million are accrued for interest at December 27, 2008 and March 29, 2008, respectively.

## Edgar Filing: HAEMONETICS CORP - Form 10-Q

We conduct business globally and, as a result, file consolidated and separate federal, state, and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world in jurisdictions including the U.S., Japan, Germany, France, the United Kingdom, and Switzerland. With few exceptions, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2005.

Table of Contents**13. COMMITMENTS AND CONTINGENCIES**

We are presently engaged in various legal actions, and although ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations.

**14. DEFINED BENEFIT PENSION PLANS**

Certain of the Company's foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:

	For the three months ended	
	December 27, 2008	December 29, 2007
	(in thousands)	
Service Cost	\$ 150	\$ 152
Interest cost on benefit obligation	66	56
Expected return on plan assets	(19)	(19)
Amortization of unrecognized prior service cost, unrecognized gain and unrecognized initial obligation	(4)	(4)
Net periodic benefit cost	\$ 193	\$ 185

	For the nine months ended	
	December 27, 2008	December 29, 2007
	(in thousands)	
Service Cost	\$ 450	\$ 438
Interest cost on benefit obligation	198	160
Expected return on plan assets	(57)	(55)
Amortization of unrecognized prior service cost, unrecognized gain and unrecognized initial obligation	(12)	(10)
Net periodic benefit cost	\$ 579	\$ 533

**15. SEGMENT INFORMATION***Segment Definition Criteria*





## Edgar Filing: HAEMONETICS CORP - Form 10-Q

We manage our business on the basis of one operating segment: the design, manufacture, marketing and delivery of blood management solutions. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product lines.

### *Enterprise Wide Disclosures about Product and Services*

We have three families of products: (1) those that serve the blood donor, (2) those that serve the patient and (3) our services and software products which are used in connections with our donor and patient products. Under the donor family of products we have included blood bank, red cell and plasma collection products. The patient products include autologous blood salvage products targeting surgical patients who lose blood during or after

Table of Contents

surgery as well as a blood loss diagnostic product. Software and services include information technology platforms, maintenance services for our donor and patient products, and business services that assist blood banks, plasma centers, and hospitals more effectively manage regulatory compliance and operational efficiency.

*Donor*

The blood bank products include devices, single use disposables and solutions that perform apheresis, as well as the washing of red blood cells for certain procedures. The main devices used for these blood component procedures are the MCS@+ mobile collection systems and the ACP@ 215 automated cell processing system.

Red cell products include devices, single use disposables and solutions that perform apheresis for the collection of red blood cells. The devices used for the collection of red blood cells is the MCS@+ 8150 mobile collection system and the Cymbal mobile collection system.

Plasma collection products are devices, disposables and solutions that perform apheresis for the separation of whole blood components and subsequent collection of plasma. The device used in automated plasma collection is the PCS@2 plasma collection system.

*Patient*

**Patient products include devices and single use disposables that process surgical blood. Patient devices include the Cell Saver and cardioPAT surgical blood salvage systems, OrthoPAT, and the SmartSuction Harmony surgical suction product. Cell Saver is used in cardiovascular surgeries with high blood loss, other high blood loss surgeries, and trauma. The Cell Saver is mainly used intra-operatively. The cardioPAT is used in lower blood loss and minimally invasive cardiovascular surgeries. The cardioPAT can be used both intra-operatively and post-operatively. OrthoPAT technology is used for lower, slower blood loss orthopedic procedures, where bleeding takes place during and after surgery. These technologies perform a procedure whereby shed blood is collected, cleansed and made available to be transfused back to the patient.**

**The SmartSuction Harmony is an auto-regulating suction system which removes blood and debris from the surgical field. The systems are used in conjunction with surgical blood salvage.**

In November of 2007, we acquired the TEG® Thrombelastograph® Hemostasis Analyzer business ( TEG® or TEGm) Haemoscope Corporation. The TEG system is a diagnostic tool which allows clinicians to determine before, during, or after surgery, the platelet function of a particular patient, and consequently the likelihood that that patient will clot or bleed and therefore, need a transfusion. The TEG system allows the surgeon or anesthesiologist to decide upon the best blood-related clinical treatment for the individual patient.

Patient products include devices and single use disposables that process surgical blood. Patient devices include the

*Software Solutions and Services*

Software and services revenue include revenue generated from Software Solutions Division, equipment repairs performed under preventive maintenance contracts or emergency service billings and miscellaneous sales and business services that assist blood banks, plasma centers, and hospitals more effectively manage regulatory compliance and operational efficiency. The Software Solutions Division provides information technology platforms and related services to plasma collectors, blood banks and the US Department of Defense. Our business services products include service offerings that assist blood banks, plasma centers, and hospitals more effectively manage regulatory compliance and operational efficiency.

Table of Contents

## Revenues from External Customers:

	Three Months Ended	
	December 27, 2008	December 29, 2007
	(in thousands)	
Disposables Revenues by Product Family		
Donor:		
Plasma	\$ 53,594	\$ 41,253
Blood Bank	36,435	33,207
Red Cell	13,051	12,478
	\$ 103,080	\$ 86,938
Patient:		
Surgical	\$ 22,967	\$ 18,981
OrthoPAT	9,112	9,086
	\$ 32,079	\$ 28,067
Disposables Revenue	\$ 135,159	\$ 115,005
Equipment	\$ 10,246	\$ 8,485
Software Solutions and Services	\$ 10,042	\$ 11,097
Total revenues from external customers	\$ 155,447	\$ 134,587

	Nine Months Ended	
	December 27, 2008	December 29, 2007
	(in thousands)	
Disposables Revenues by Product Family		
Donor:		
Plasma	\$ 150,386	\$ 114,789
Blood Bank	108,388	100,399
Red Cell	36,651	34,257
	\$ 295,425	\$ 249,445
Patient:		
Surgical	\$ 66,077	\$ 50,907
OrthoPAT	26,301	25,122
	\$ 92,378	\$ 76,029
Disposables Revenue	\$ 387,803	\$ 325,474
Equipment	\$ 27,388	\$ 22,286
Software Solutions and Services	\$ 30,291	\$ 29,941
Total revenues from external customers	\$ 445,482	\$ 377,701

Table of Contents

**16. REORGANIZATION**

During the last two years, the Company embarked on a business transformation with the primary focus on our international businesses. The goal of the transformation was to position these businesses to complement the growth of our U.S. business.

On May 1, 2008, management announced a plan to transform our Technical Operations organization, which includes research, development and engineering, quality systems and manufacturing. Our goal is to better align our Technical Operations resources with our strategy to be the global leader in blood management solutions for our customers. This transformation will include: optimizing the products manufactured in our plants to best support our global customer base and concentrating our research, development and engineering resources on one platform project at a time.

Over the course of fiscal year 2009, we intend to finalize and implement the Technical Operations organization transformation plan. In accordance with the Company's revised guidance, once finalized and implemented, we expect to incur exit related costs in the range of \$6 million to \$7 million.

We expect this transformation will align our resources with our vision of being the global leader in blood management solutions.

We are also finalizing the consolidation of our customer support functions in Europe into our European Headquarters in Signy, Switzerland. The consolidated center in Signy now includes finance, customer and sales support, and logistics supply chain management. The majority of the consolidation of these functions occurred during fiscal year 2008.

For the nine months ended December 27, 2008 and December 29, 2007, we recorded pre-tax restructuring costs of \$2.1 million and \$2.9 million, respectively, as selling, general, and administrative costs. Additionally, we incurred other transformation costs relating to the hiring of personnel in our new shared services center in Signy, Switzerland of \$0.5 million and \$0.7 million for the nine months ended December 27, 2008 and December 29, 2007, respectively. The other transformation costs related to the hiring of personnel are not included in the table below.

The following summarizes the restructuring activity for the nine months ended December 27, 2008 and December 29, 2007, respectively:

Table of Contents**Nine Months Ended December 27, 2008**

(Dollars in thousands)	Balance at March 29, 2008	Cost Incurred	Payments	Asset Write down	Restructuring Accrual Balance at December 27, 2008
Employee-related costs	\$ 521	\$ 1,994	\$ (1,886)	\$	\$ 629
Facility related costs	42	71	(71)		42
Other Exit & Termination Costs	78				78
	\$ 641	\$ 2,065	\$ (1,957)	\$	\$ 749

**Nine Months Ended December 29, 2007**

(Dollars in thousands)	Balance at March 31, 2007	Cost Incurred	Payments	Asset Write down	Restructuring Accrual Balance at December 29, 2007
Employee-related costs	\$	\$ 2,195	\$ (1,791)	\$	\$ 404
Facility related costs		688	(514)	(86)	88
	\$	\$ 2,883	\$ (2,305)	\$ (86)	\$ 492

**17. CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS**

The Company is implementing an Enterprise Resource Planning (ERP) system. In Fiscal 2007, we began our plan to implement the system in two phases over three years. The Company has completed and put into service costs relating to Phase I. Phase II began during the three months ended June 28, 2008.

The cost of software that is developed for internal use is accounted for pursuant to AICPA Statement of Position 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use (SOP 98-1). Pursuant to SOP 98-1, the Company capitalizes costs incurred during the application development stage of software developed for internal use, and expenses costs incurred during the preliminary project and the post-implementation operation stages of development. The Company capitalized \$4.5 million and \$6.5 million, respectively, during the nine month periods ended December 27, 2008 and December 29, 2007, in costs incurred for acquisition of the software license and related software development costs for new internal software development that was in the application stage. Since project inception, the total capitalized costs incurred include \$1.8 million for the cost of the software license and \$17.4 million in third party and internal personnel development costs.

SFAS No. 86, Accounting for the Cost of Computer Software to be Sold, Leased or Otherwise Marketed, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. In connection with the development of the software for our next generation Donor apheresis platform, the Company capitalized \$0.8 million during the nine month period ended December 27, 2008 and a project to date total of \$11.9 million. All costs capitalized were incurred after a detailed design of the software was developed and research and development activities on the underlying device were completed. Work on the Donor apheresis platform has been temporarily suspended while the Company focuses on completing another project, which is expected to be completed by early to mid fiscal year 2010. Work on the Donor apheresis platform is expected to resume during fiscal year 2010. We will begin to amortize these costs when the device is released for sale.

Additionally, the Company capitalized \$2.3 million in software development costs for other ongoing initiatives during the nine month period ended December 27, 2008. We will begin to amortize these costs when the products are released for sale.

**18. SUBSEQUENT EVENT**

On January 30, 2009, a jury returned a verdict in favor of the Company in a patent infringement case pending in the federal district court of Massachusetts since December 2005 (Haemonetics Corporation v. Baxter Healthcare Corporation et al. (CV No. 05-12572-NMG)(D.Ct. MA)). The jury determined that Fenwal's Alyx system infringes a Haemonetics patent and awarded the Company damages for lost profits and royalties in the approximate amount of \$15.7 million. The verdict is subject to appeal.



Table of Contents

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

This Management's Discussion and Analysis of Financial Condition and Results of Operations ( MD&A ) should be read in conjunction with both our interim consolidated financial statements and notes thereto which appear elsewhere in this Quarterly Report on Form 10-Q, the consolidated financial statements and notes thereto, and the MD&A contained in our fiscal year 2008 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC ) on May 27, 2008. The following discussion may contain forward-looking statements and should be read in conjunction with the **Cautionary Statement Regarding Forward-Looking Information** beginning on page 40.

**Our Business**

Haemonetics is a blood management solutions company for our customers. Anchored by our reputable medical devices systems, we also provide information technology platforms and value added services to provide customers with business solutions which support improved clinical outcomes for patients and efficiency in the blood supply chain.

Our systems automate the collection and processing of donated blood; assess likelihood for blood loss; and salvage and process surgical patient blood. These systems include devices and single-use, proprietary disposable sets ( disposables ) that operate only with our specialized devices. Our systems allow users to collect and process only the blood component(s) they target plasma, platelets, or red blood cells increasing donor and patient safety as well as collection efficiencies. Our information technology platforms are used by blood and plasma collectors to improve the safety and efficiency of blood collection logistics by eliminating previously manual functions at not-for-profit blood banks and commercial plasma centers. Our business services products include consulting, Six Sigma, LEAN manufacturing and Insight Opportunity Model offerings that support our customers' needs for regulatory compliance and operational efficiency in the blood supply chain.

We either sell our devices to customers (resulting in equipment revenue) or place our devices with customers subject to certain conditions. When the device remains our property, the customer has the right to use it for a period of time as long as the customer meets certain conditions we have established, which among other things, generally include one or more of the following:

- Purchase and consumption of a minimum level of disposables products;
- Payment of monthly rental fees; and
- An asset utilization performance metric, such as performing a minimum level of procedures per month per device.

Our disposables revenue stream (including sales of disposables and fees for the use of our equipment) accounted for approximately 86.9% and 85.5% of our total revenues for the third quarter of fiscal year 2009 and 2008, respectively and 87.1% and 86.2% of our total revenues for the first nine months of fiscal year 2009 and 2008, respectively.



Table of Contents**Financial Summary**

(in thousands, except per share data)	For the three months ended			For the nine months ended		
	December 27, 2008	December 29, 2007	% Increase/ (Decrease) Q3FY09 vs. Q3FY08	December 27, 2008	December 29, 2007	% Increase/ (Decrease) YTDFY09 vs. YTDFY08
Net revenues	\$ 155,447	\$ 134,587	15.5%	\$ 445,482	\$ 377,701	17.9%
Gross profit	\$ 78,296	\$ 66,558	17.6%	\$ 226,022	\$ 187,940	20.3%
<i>% of net revenues</i>	50.4%	49.5%		50.7%	49.8%	
Operating income	\$ 24,491	\$ 19,597	25.0%	\$ 67,434	\$ 49,990	34.9%
<i>% of net revenues</i>	15.8%	14.6%		15.1%	13.2%	
Interest income, net	\$ 449	\$ 1,070	(58.0)%	\$ 1,569	\$ 4,037	(61.1)%
Other income/(expense), net	\$ (1,451)	\$ 225	(744.9)%	\$ (2,366)	\$ 1,905	(224.2)%
Income before taxes	\$ 23,489	\$ 20,892	12.4%	\$ 66,637	\$ 55,932	19.1%
Provision for income tax	\$ 7,273	\$ 6,538	11.2%	\$ 21,272	\$ 17,733	20.0%
<i>% of pre-tax income</i>	31.0%	31.3%		31.9%	31.7%	
Net income	\$ 16,216	\$ 14,354	13.0%	\$ 45,365	\$ 38,199	18.8%
<i>% of net revenues</i>	10.4%	10.7%		10.2%	10.1%	
Earnings per share-diluted	\$ 0.62	\$ 0.54	14.6%	\$ 1.73	\$ 1.43	21.5%

Net revenues increased 15.5% and 17.9% for the third quarter and the first nine months of fiscal year 2009 over the comparable period of fiscal year 2008. The effects of foreign exchange accounted for an increase of 1.0% and 3.7% for the third quarter and nine months, respectively. The remaining increase of 14.5% for the quarter and 14.2% for the nine months is mainly due to increases in our disposables revenue and equipment sales. The increase in disposables revenue for the quarter resulted primarily from disposable unit increases in Plasma and Surgical & Diagnostic. Surgical & Diagnostic disposables revenue include \$5.3 million and \$15.0 million of revenues for the third quarter and nine months, respectively related to the TEG® Thrombelastograph® Hemostasis Analyzer business ( TEG® or TEG ) which was acquired in the third quarter of fiscal year 2008 and the Medicell business which was acquired in the first quarter of fiscal year 2009.

Gross profit increased 17.6% and 20.3% for the third quarter and the first nine months of fiscal year 2009 over the comparable period of fiscal year 2008. The favorable effects of foreign exchange accounted for an increase of 2.6% and 5.7% for the third quarter and first nine months of fiscal year 2009, respectively. The remaining

Table of Contents

increase of 15.0% for the quarter and 14.6% for the nine months was due primarily to increased sales offset partly by changes in product mix driven by higher sales of lower margin plasma products.

Operating income increased 25.0% and 34.9% for the third quarter and the first nine months of fiscal year 2009 over the comparable period of fiscal year 2008. The favorable effects of foreign exchange accounted for an increase of 13.1% and 14.6% for the third quarter and the first nine months of fiscal year 2009, respectively. Without the effects of foreign exchange, operating income increased 11.9% for the quarter and 20.3% for the nine months. These increases were a result of the gross profit changes described above offset by higher operating expenses of 16.3% and 12.3% for the third quarter and first nine months of fiscal year 2009, respectively. The noted higher operating expenses are largely related to the expenses from the recent acquisitions, including TEG® and increased employee performance based compensation expense in the third quarter and first nine months of fiscal year 2009 based on strong Company performance versus pre-established targets.

Net income increased 13.0% and 18.8% for the third quarter and the first nine months of fiscal year 2009 over the comparable periods of fiscal year 2008. The main factor that affected net income was the increase in operating income, due to the reasons mentioned above and a reduction in interest and other income. The increase in operating income was partially offset by lower interest income and by higher other expense, net relating to lower cash on hand stemming from the TEG® business acquisition and share repurchase program, and lower investment yield.

**RESULTS OF OPERATIONS****Net Revenues  
by Geography**

(in thousands)	For the three months ended			For the nine months ended		
	December 27, 2008	December 29, 2007	% Increase Q3FY09 vs. Q3FY08	December 27, 2008	December 29, 2007	% Increase YTDFY09 vs. YTDFY08
United States	\$ 73,448	\$ 61,481	19.5%	\$ 205,748	\$ 170,085	21.0%
International	81,999	73,106	12.2%	239,734	207,616	15.5%
<b>Net revenues</b>	<b>\$ 155,447</b>	<b>\$ 134,587</b>	<b>15.5%</b>	<b>\$ 445,482</b>	<b>\$ 377,701</b>	<b>17.9%</b>

**International Operations and the Impact of Foreign Exchange**

Our principal operations are in the U.S., Europe, Japan and other parts of Asia. Our products are marketed in more than 50 countries around the world via a direct sales force as well as independent distributors.

Our revenues generated outside the U.S. approximated 52.8% and 54.3% of total sales for the third quarter of fiscal years 2009 and 2008, respectively and 53.8% and 55.0% for the first nine months of fiscal years 2009 and 2008, respectively. Revenues in Japan accounted for

## Edgar Filing: HAEMONETICS CORP - Form 10-Q

approximately 17.7% and 16.4% of total revenues for the third quarter of fiscal year 2009 and 2008, respectively and 16.5% and 17.6% of total revenues for the first nine months of fiscal year 2009 and 2008, respectively. Revenues in Europe accounted for approximately 27.6% and 30.8% of total revenues for the third quarters of fiscal year 2009 and 2008 and 29.5% and 29.7% of total revenues for the first nine months of fiscal year 2009 and 2008, respectively. International sales are primarily conducted in local currencies, primarily the Japanese Yen and the Euro. As discussed above, our results of operations can be impacted by changes in the value of the Yen and the Euro relative to the U.S. dollar.

Edgar Filing: HAEMONETICS CORP - Form 10-Q

Table of Contents

Please see section entitled "Foreign Exchange" in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure.

Net Revenues

By Product Type

(in thousands)	For the three months ended			For the nine months ended		
	December 27, 2008	December 29, 2007	% Increase / (Decrease) Q3FY09 vs. Q3FY08	December 27, 2008	December 29, 2007	% Increase YTD FY09 vs. YTD FY08
Disposables	\$ 135,159	\$ 115,005	17.5%	\$ 387,803	\$ 325,473	19.2%
Software Solutions & Service	10,042	11,097	(9.5)%	30,291	29,942	1.2%
Equipment	10,246	8,485	20.8%	27,388	22,286	22.9%
<b>Net revenues</b>	<b>\$ 155,447</b>	<b>\$ 134,587</b>	<b>15.5%</b>	<b>\$ 445,482</b>	<b>\$ 377,701</b>	<b>17.9%</b>

Disposables Revenues

By Product Type

(in thousands)	For the three months ended			For the nine months ended		
	December 27, 2008	December 29, 2007	% Increase Q3FY09 vs. Q3FY08	December 27, 2008	December 29, 2007	% Increase YTD FY09 vs. YTD FY08
<u>Donor:</u>						
Plasma	\$ 53,594	\$ 41,253	29.9%	\$ 150,386	\$ 114,788	31.0%
Blood Bank	36,435	33,207	9.7%	108,388	100,399	8.0%
Red Cell	13,051	12,478	4.6%	36,651	34,257	7.0%
<b>Subtotal</b>	<b>\$ 103,080</b>	<b>\$ 86,938</b>	<b>18.6%</b>	<b>\$ 295,425</b>	<b>\$ 249,444</b>	<b>18.4%</b>
<u>Patient:</u>						
Surgical & Diagnostic	\$ 22,967	\$ 18,981	21.0%	\$ 66,077	\$ 50,907	29.8%
OrthoPat	9,112	9,086	0.3%	26,301	25,122	4.7%
<b>Subtotal</b>	<b>\$ 32,079</b>	<b>\$ 28,067</b>	<b>14.3%</b>	<b>\$ 92,378</b>	<b>\$ 76,029</b>	<b>21.5%</b>
<b>Total disposables revenue</b>	<b>\$ 135,159</b>	<b>\$ 115,005</b>	<b>17.5%</b>	<b>\$ 387,803</b>	<b>\$ 325,473</b>	<b>19.2%</b>

**DONOR PRODUCTS**

## Edgar Filing: HAEMONETICS CORP - Form 10-Q

Donor products include the plasma, blood bank and red cell product lines. Disposables revenue for donor products increased 18.6% compared to the third quarter of fiscal year 2008 and 18.4% for the first nine months over the comparable period in fiscal year 2008. Foreign exchange resulted in a 2.0% increase for the third quarter and 4.4% increase for the first nine months over the comparable period in fiscal year 2008. The remaining increase of 16.6% for the quarter and 14.0% for the first nine months was driven by increases in Plasma along with increases in the other product lines, as discussed below.

Table of Contents

Plasma

Plasma disposable revenue increased 29.9% and 31.0% for the third quarter and the first nine months of fiscal year 2009 over the comparable periods of fiscal year 2008. Foreign exchange resulted in a 0.7% decrease and 2.6% increase on plasma disposables revenue for the quarter and the first nine months, respectively.

The two main reasons for the remaining increase for the quarter and for the first nine months are (1) increased demand for our products due to the demand for plasma derived pharmaceuticals and (2) a larger installed base of our plasma devices caused by the addition of new customers added over the last twelve months. Demand for source plasma to make pharmaceuticals remains strong, increasing collections by our customers and resulting in higher sales. To meet this higher demand, over the past year we have continued to place additional equipment with existing and new customers. Over the next twelve to twenty-four months, as market growth rates trend down and our customers' demand levels normalize, we expect plasma disposable growth rates to moderate to a low double-digit rate.

Blood Bank

Blood bank disposable revenue for donor products increased 9.7% and 8.0%, respectively, for the third quarter and the first nine months of fiscal year 2009 compared to the same periods in of fiscal year 2008. Foreign exchange resulted in a 6.2% increase in blood bank disposables revenue during the quarter and 7.1% increase in the first nine months over the comparable periods in fiscal year 2008. Without the effect of currency, blood bank revenue increased 3.5% and 0.9% for the third quarter and first nine months.

Blood bank sales consist of our products which collect platelets, and certain blood processing equipment. The increase was driven by increased sales to Canadian Blood Services and the Asia Pacific region partially offset by declines in European direct sales and Japan. While the overall market for platelet collections has seen nominal growth rates in Europe, U.S. and Japan, we have seen increased demand in certain emerging markets which has driven increased sales in those geographies. The sales to the Canadian Blood Services are the result of a contract implemented in the fourth quarter of fiscal year 2008.

Red Cell

Red cell disposable revenue increased 4.6% compared to the third quarter of fiscal year 2008 and 7.0% compared to the first nine months of fiscal year 2008. Foreign exchange accounted for a decrease of 1.2% in the quarter and an increase of 1.4% for the first nine months over the comparable period in fiscal year 2008. Without this effect, disposables revenue increased 5.8% for the quarter and 5.6% for the first nine months.

Our red cell products are sold primarily to blood collectors, such as blood banks and government agencies. Sales are driven by the total level of red cell collections, the percentage of those collections done with apheresis devices and our market share of those automated collections. With worldwide blood donation increasing low single digits, sales increases are driven primarily by collectors adopting our apheresis technology over



manual whole blood collection. The quarterly and year-to-date increases were primarily due to additional equipment placements over the last year in North America and increased direct sales in Europe.

## **PATIENT PRODUCTS**

The patient product line includes the following brand platforms: the Cell Saver® brand, the TEG® products, the OrthoPAT® brand, the cardioPAT® brand, and the SmartSuction Harmony products. Patient disposables revenue increased 14.3% compared to the third quarter of fiscal year 2008 and 21.5% compared to the first nine months of fiscal year 2008. Foreign exchange resulted in a 0.3% increase in patient disposables revenue during the quarter and a 3.0% increase during the first nine months. The remaining increase of 14.0% for the quarter and

Table of Contents

18.5% for the first nine months were the result of increases in each of the product lines and the acquisition of the TEG products, as discussed below.

Surgical & Diagnostic

Revenues from our surgical disposables and diagnostic products increased 21.0% as compared to the third quarter of fiscal year 2008 and increased 29.8% as compared to the first nine months of fiscal 2008. Surgical and diagnostic disposables revenue consists principally of the Cell Saver, cardioPAT, and TEG products. Foreign exchange resulted in a 0.1% increase in surgical and diagnostic disposables revenue during the quarter and a 3.1% increase the first nine months. Without the effect of currency, surgical disposables and diagnostic revenue increased 20.9% for the quarter and 26.7% for the first nine months. The growth is principally driven by the impact of adding the TEG® product line, which had sales of \$5.3 million in the third quarter and \$15.0 million in the first nine months of fiscal year 2009, to the surgical product portfolio. The TEG product line was added through its acquisition from Haemoscope Corporation in the third quarter of fiscal year 2008. In the first quarter of fiscal year 2009, Medicell (previously, Haemoscope's UK distributor) was acquired.

OrthoPAT

OrthoPAT disposables revenue increased 0.3% as compared to the third quarter of fiscal year 2008 and 4.7% for the first nine months of fiscal 2008. Foreign exchange resulted in a 0.4% increase in OrthoPAT disposables revenue during the quarter and a 2.5% increase for the first nine months. Without foreign exchange, revenues decreased by 0.1% and increased by 2.2%, respectively for the third quarter and the first nine months of fiscal year 2009 compared to the same period in fiscal year 2008. The growth for the first nine months was driven by increases in Japan and European markets.

Our OrthoPAT products serve orthopedic procedures that involve slower, lower volume blood loss that occurs during surgery and for blood loss that occurs for up to six hours after surgery. Revenues are driven by adoption of the technology by surgeons and hospitals, and particularly by increased usage among existing customers.

**OTHER REVENUES**

(in thousands)	For the three months ended			% (Decrease) / Increase Q3FY09 vs. Q3FY08	For the nine months ended			% Increase YTDFY09 vs. YTDFY08
	December 27, 2008	December 29, 2007			December 27, 2008	December 29, 2007		
Software Solutions and Services	\$ 10,042	\$ 11,097		(9.5)%	\$ 30,291	\$ 29,941		1.2%
Equipment	10,246	8,485		20.8%	27,388	22,286		22.9%
<b>Total other revenues</b>	<b>\$ 20,288</b>	<b>\$ 19,582</b>		<b>3.6%</b>	<b>\$ 57,679</b>	<b>\$ 52,227</b>		<b>10.4%</b>

## Edgar Filing: HAEMONETICS CORP - Form 10-Q

Our software solutions and services revenues include revenue from software sales and services revenues derived from repairs performed under preventive maintenance contracts or emergency service visits, spare part sales, and various service and training programs.

Software solutions and services revenues decreased 9.5% for the third quarter and increased 1.2% for the first nine months as compared to the same periods of fiscal year 2008. Software solutions revenues increased 12.2%

Table of Contents

and 25.7% as compared to the third quarter and first nine months of fiscal year 2008, respectively. Foreign exchange had only a minor impact on the results as sales were primarily in U.S. dollars. The increase was driven by increased sales to commercial plasma customers. Services revenues declined 43.3% and 33.1% as compared to the third quarter and first nine months of fiscal year 2008, respectively. Without foreign exchange, services revenues decreased by 34.0% and 34.6% for the third quarter and first nine months of fiscal year 2009 as compared to the same periods in fiscal year 2008. The decrease in revenues is primarily due to the completion of a non-recurring consulting contract in North America where service was performed through the first nine months of fiscal year 2008 and was completed toward the end of fiscal year 2008.

Revenue from equipment sales increased 20.8% as compared to the third quarter of fiscal year 2008 and 22.9% for the first nine months compared to that of fiscal year 2008. Foreign exchange resulted in a 2.4% increase in equipment revenue during the quarter and 4.3% increase for the first nine months. The remaining increase of 18.4% for the quarter and 18.6% for the first nine months over the same periods of fiscal year 2008 relates to platelet equipment sales primarily in distribution markets and cell processing equipment to military customers.

**Gross Profit**

(in thousands)	For the three months ended			For the nine months ended		
	December 27, 2008	December 29, 2007	% Increase Q3FY09 vs. Q3FY08	December 27, 2008	December 29, 2007	% Increase YTDFY09 vs. YTDFY08
<b>Gross Profit</b>	\$ 78,296	\$ 66,558	17.6%	\$ 226,022	\$ 187,940	20.3%
<b>Gross Profit Margin</b>	50.4%	49.5%		50.7%	49.8%	

Gross profit increased 17.6% and 20.3%, respectively, as compared to the third quarter and first nine months of fiscal year 2008. Foreign exchange resulted in an increase in gross profit of 2.6% for the quarter and 5.7% for the first nine months as compared to fiscal year 2008. The remaining increase of 15.0% for the quarter and 14.6% for the first nine months was due primarily to the net increase in sales. Gross margin percent improved 90 basis points for the first nine months of fiscal year 2009 as compared to the same period of fiscal year 2008. Major factors impacting the gross margin percent improvement of 90 basis points included foreign exchange impact, manufacturing efficiencies, and product mix.

Table of Contents**Operating Expenses**

(in thousands)	For the three months ended			For the nine months ended		% (Decrease) / Increase YTDFY09 vs. YTDFY08
	December 27, 2008	December 29, 2007	% Increase Q3FY09 vs. Q3FY08	December 27, 2008	December 29, 2007	
Research and development	\$ 5,840	\$ 5,529	5.6%	\$ 16,901	\$ 18,532	(8.8)%
% of net revenues	3.8%	4.1%		3.8%	4.9%	
Selling, general and administrative	\$ 47,965	\$ 41,432	15.8%	\$ 141,687	\$ 119,418	18.6%
% of net revenues	30.9%	30.8%		31.8%	31.6%	
Total Operating Expenses	\$ 53,805	\$ 46,961		\$ 158,588	\$ 137,950	
% of net revenues	34.6%	34.9%		35.6%	36.5%	

**Research and Development**

Research and development expenses increased 5.6% and decreased 8.8%, respectively, as compared to the same quarter and first nine months of fiscal year 2008. The significant factors in the increase for the quarter are increased research and development investments in the Arryx technology. The decrease for the first nine months is attributable to lower spending in certain core technology projects, as we rationalized our research and development activities to focus on one platform at a time.

**Selling, General and Administrative**

Selling, general and administrative expenses increased 15.8% in the third quarter of fiscal year 2009 and 18.6% for the first nine months of fiscal year 2009 as compared to the comparable periods of fiscal year 2008. Foreign exchange resulted in a 2.1% decrease in selling, general and administrative during the quarter and a 3.3% increase during the first nine months. Excluding the impact of foreign exchange, selling, general and administrative expense increased 17.9% for the third quarter and 15.3% for the first nine months as compared to the comparable periods in fiscal year 2008. The increase was due largely to expenses brought on from recent acquisitions of the TEG® Thrombelastograph® Hemostasis Analyzer business, Medicell, and Infonalé (blood management consulting services business) that had not been fully reflected in the third quarter or first nine months of fiscal year 2008 and increased employee performance based compensation expense in the third quarter and first nine months of fiscal year 2009 based on strong Company performance versus pre-established targets.



Table of Contents**Operating Income**

(in thousands)	For the three months ended		% Increase Q3FY09 vs. Q3FY08	For the nine months ended		% Increase YTDFY09 vs. YTDFY08
	December 27, 2008	December 29, 2007		December 27, 2008	December 29, 2007	
<b>Operating income</b>	\$ 24,491	\$ 19,597	25.0%	\$ 67,434	\$ 49,990	34.9%
<i>% of net revenues</i>	15.8%	14.6%		15.1%	13.2%	

Operating income increased 25.0% and 34.9%, respectively, as compared to the third quarter and first nine months of fiscal year 2008. Foreign exchange resulted in a 13.1% increase in operating income during the quarter and 14.6% increase during the first nine months. Without the effects of foreign currency, operating income increased 11.9% for the quarter and 20.3% for the first nine months due primarily to sales and gross profit growth, partially offset by increases in operating expenses.

**Other income, net**

(in thousands)	For the three months ended		% Decrease Q3FY09 vs Q3FY08	For the nine months ended		% Decrease YTDFY09 vs. YTDFY08
	December 27, 2008	December 29, 2007		December 27, 2008	December 29, 2007	
Interest income, net	449	1,070		1,569	4,037	
Other income/(expense), net	(1,451)	225		(2,366)	1,905	
<b>Total other income/(expense), net</b>	\$ (1,002)	\$ 1,295	(177.4)%	\$ (797)	\$ 5,942	(113.4)%

Total other income, net decreased 177.4% during the third quarter of fiscal year 2009 as compared to the third quarter of fiscal year 2008 and decreased 113.4% during the nine month period of fiscal year 2009 as compared to the nine month period of fiscal year 2008 due to the net of the (i) decrease in interest income due to lower interest rates and lower invested cash resulting from acquisitions and the Company's share repurchase program, (ii) decrease in interest expense resulting from lower average fixed rate debt outstanding, (iii) increase in other expense associated with hedge points on forward contracts and (iv) foreign exchange losses on foreign currency denominated assets. Points on forward contracts are amounts, either expensed or earned, based on the interest rate differential between two foreign currencies in a forward hedge contract.

**Income Taxes**

Our reported tax rate includes two principal components: an annual effective tax rate and discrete items that are recorded in the quarter that an event occurs. Events or items that give rise to discrete recognition include finalizing audit examinations for open tax years and a statute of limitation's expiration.





Table of Contents

	For the three months ended		For the nine months ended	
	December 27, 2008	December 29, 2007	December 27, 2008	December 29, 2007
Annual Effective Tax Rate	35.1%	35.9%	35.1%	35.0%
Discrete Items	(4.1)%	(4.6)%	(3.2)%	(3.3)%
Reported Income Tax Rate	31.0%	31.3%	31.9%	31.7%

The annual effective rate for the three months ended December 27, 2008 was 35.1%, a decrease of 0.8% over the three months ended December 29, 2007. This decrease is a result of changes in the global distribution of our income, partially offset by a reduction in tax exempt income. The annual effective rate for the nine months ended December 27, 2008 was 35.1%, an increase of 0.1% over the nine months ended December 29, 2007. This increase is a result of a reduction in tax exempt income, partially offset by a change in the global distribution of our income.

Discrete tax benefits were recognized in the three months ended December 27, 2008 and December 29, 2007. For the third quarter of fiscal 2009, the discrete benefits totaled \$973,000. The noted discrete benefits were comprised of the release of \$1.1 million tax reserves due to a statute of limitations expiration and a \$135,000 discrete benefit for the reinstated research & development credit for the first and second quarter of fiscal 2009 that was offset in part by a \$301,000 tax provision due to the finalization of our fiscal 2008 U.S. Federal income tax returns. For the nine months ended December 27, 2008 discrete tax benefits totaled \$2.1 million, including the amounts described above, and benefits of \$1.2 million related to a statute of limitations expiration in Japan.

We conduct business globally and, as a result, file consolidated and separate federal, state, and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world in jurisdictions including the U.S., Japan, Germany, France, the United Kingdom, and Switzerland. With few exceptions, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2005.

**Liquidity and Capital Resources**

The following table contains certain key performance indicators we believe depict our liquidity and cash flow position:

	December 27, 2008	March 29, 2008
	(dollars in thousands)	
Cash & cash equivalents	\$ 125,325	\$ 133,553
Working capital	\$ 268,358	\$ 261,757
Current ratio	4.1	3.7
Net cash position (1)	\$ 115,369	\$ 121,190
Days sales outstanding (DSO)	72	78
Disposables finished goods inventory turnover	7.1	6.9

(1) Net cash position is the sum of cash and cash equivalents less total debt.



Table of Contents

Our primary sources of capital include cash and cash equivalents, internally generated cash flows, bank borrowings and option exercises. We believe these sources to be sufficient to fund our requirements, which are primarily capital expenditures and acquisitions, new business and product development, and working capital for at least the next twelve months.

	December 27, 2008		December 29, 2007		\$ Increase / (Decrease)
	(dollars in thousands)				
Net cash provided by (used in):					
Operating activities	\$	72,658	\$	45,790	\$ 26,868
Investing activities		(45,607)		(85,728)	40,121
Financing activities		(33,880)		(73,455)	39,575
Effect of exchange rate changes on cash (1)		(1,399)		1,023	(2,422)
Net decrease in cash and cash equivalents	\$	(8,228)	\$	(112,370)	\$ 104,142

(1) The balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. dollars. In accordance with GAAP, we have removed the effect of foreign currency throughout our cash flow statement, except for its effect on our cash and cash equivalents.

Through December 27, 2008, the Company repurchased approximately 1,100,000 shares of its common stock for an aggregate purchase price of \$60.0 million. This completed a \$60.0 million share repurchase program that was announced in May 2008. We reflect stock repurchases in our financial statements on a trade date basis and as Authorized Unissued (Haemonetics is a Massachusetts company and under Massachusetts law repurchased shares are treated as authorized but unissued).

**Cash Flow Overview:**



**Nine Month Comparison**



*Operating Activities:*





## Edgar Filing: HAEMONETICS CORP - Form 10-Q

Net cash provided by operating activities increased by \$26.9 million in the first nine months of fiscal year 2009 as compared to 2008 due primarily to:

- Increased net income adjusted for non-cash items,
- Reduced investment in accounts receivable as our collections improved, particularly in Europe,

partially offset by

- A \$6.4 million increased investment in inventories associated with increased levels of business.

### ***Investing Activities:***



## Edgar Filing: HAEMONETICS CORP - Form 10-Q

Net cash used in investing activities decreased by \$40.1 million during the first nine months of fiscal year 2009 as compared to 2008 due primarily to the \$43.9 million decreased investment in acquisitions net of a \$3.2 million increase capital expenditures on property, plant and equipment.







*Table of Contents*





*Financing Activities:*



## Edgar Filing: HAEMONETICS CORP - Form 10-Q

Net cash used in financing activities decreased by \$39.6 million in the first nine months of fiscal year 2009 as compared to 2008 due primarily to:

- \$15.0 million decrease in money spent relating to stock repurchase, a \$10.2 million increase in exercise of stock options and tax benefit of stock compensation, \$8.2 million net increase in short-term revolving credit agreements, and a \$5.7 million decrease in payments on credit agreements.

### *Inflation*



We do not believe that inflation had a significant impact on our results of operations for the periods presented. Historically, we believe we have been able to mitigate the effects of inflation by improving our manufacturing and purchasing efficiencies, by increasing employee productivity, and by adjusting the selling prices of products. We continue to monitor inflation pressures generally and raw materials indices that may affect our procurement and production costs. Increases in the price of petroleum derivatives could result in corresponding increases in our costs to procure plastic raw materials.

### *Foreign Exchange*

Through the first nine months of fiscal year 2009, 53.8% of our sales are generated outside the U.S. in local currencies, yet our reporting currency is the U.S. dollar. Our primary foreign currency exposures in relation to the U.S. dollar are the Japanese Yen and the Euro. Foreign exchange risk arises because we engage in business in foreign countries in local currency. Exposure is partially mitigated by producing and sourcing product in local currency and expenses incurred by local sales offices. However, whenever the U.S. dollar strengthens relative to the other major currencies, there is an adverse affect on our results of operations and alternatively, whenever the U.S. dollar weakens relative to the other major currencies there is a positive effect on our results of operations.

It is our policy to minimize for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge the anticipated cash flows from forecasted foreign currency denominated sales. Hedging through the use of forward contracts does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. We enter into forward contracts that mature one month prior to the anticipated timing of the forecasted foreign currency denominated sales. These contracts are designated as cash flow hedges and are intended to lock in the expected cash flows of forecasted foreign currency denominated sales at the available spot rate. Actual spot rate gains and losses on these contracts are recorded in sales, at the same time the underlying transactions being hedged are recorded.

We compute a composite rate index for purposes of measuring, comparatively, the change in foreign currency hedge spot rates from the hedge spot rates of the corresponding period in the prior year. The relative value of currencies in the index is weighted by sales in those currencies. The composite was set at 1.00 based upon the weighted rates at March 31, 1997. The composite rate is presented in the period corresponding to the maturity of the underlying forward contracts.

The favorable or (unfavorable) changes are in comparison to the same period of the prior year. A favorable change is presented when we will obtain relatively more U.S. dollars for each of the underlying foreign currencies than we did in the prior period. An unfavorable change is presented when we obtain relatively fewer U.S. dollars for each of the underlying foreign currencies than we did in the prior period. These indexed hedge rates impact sales, and as a result also gross profit, operating income and net income, in our consolidated financial statements. The final impact of currency fluctuations on the results of operations is dependent on the local currency amounts hedged and the actual local currency results.

Edgar Filing: HAEMONETICS CORP - Form 10-Q

Table of Contents

		Composite Index Hedge Spot Rates	Favorable / (Unfavorable) Change versus Prior Year
<b>FY2005</b>	Q1	0.97	15.7%
	Q2	0.99	5.1%
	Q3	0.92	15.5%
	Q4	0.89	14.1%
<b>2005</b>	<b>Total</b>	<b>0.94</b>	<b>12.7%</b>
<b>FY2006</b>	Q1	0.92	5.2%
	Q2	0.91	9.1%
	Q3	0.87	5.7%
	Q4	0.86	2.8%
<b>2006</b>	<b>Total</b>	<b>0.89</b>	<b>5.1%</b>
<b>FY2007</b>	Q1	0.89	3.6%
	Q2	0.92	(1.1)%
	Q3	0.96	(9.4)%
	Q4	0.95	(9.3)%
<b>2007</b>	<b>Total</b>	<b>0.93</b>	<b>(4.2)%</b>
<b>FY2008</b>	Q1	0.92	(3.1)%
	Q2	0.93	(1.0)%
	Q3	0.93	3.3%
	Q4	0.93	2.4%
<b>2008</b>	<b>Total</b>	<b>0.93</b>	<b>0.4%</b>
<b>FY2009</b>	Q1	0.92	0.5%
	Q2	0.90	3.4%
	Q3	0.86	8.3%
	Q4	0.82	13.9%
		<b>0.87</b>	<b>6.3%</b>
<b>FY2010</b>	Q1	0.77	19.5%
	Q2	0.81	10.4%
	Q3	0.83	3.1%
		<b>0.81</b>	<b>7.9%</b>

**Recent Accounting Pronouncements**





## Edgar Filing: HAEMONETICS CORP - Form 10-Q

In September 2008, the FASB issued FASB Staff Position (FSP) No. 133-1 and FIN 45-4, Disclosures about Credit Derivatives and Certain Guarantees: An Amendment of FASB Statement No. 133 and FASB Interpretation No. 45 . The FSP is intended to improve disclosures about credit derivatives by requiring more information about the potential adverse effects of changes in credit risk on the financial position, financial performance, and cash flows of the sellers of credit derivatives. It amends FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities , to require disclosures by sellers of credit derivatives, including credit derivatives embedded in hybrid instruments. The provisions of the FSP that amend Statement 133 and Interpretation 45 are effective for reporting periods (annual or interim) ending after November 15, 2008. These statements became effective during this quarter and did not have an impact on our financial position and results of operation as we have not issued or purchased credit derivatives.

Table of Contents

In May 2008, the FASB issued SFAS No. 162, *The Hierarchy of Generally Accepted Accounting Principles*, which will provide framework for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (GAAP) for nongovernmental entities. Prior to the issuance of SFAS No. 162, the GAAP hierarchy was defined in the American Institute of Certified Public Accountants (AICPA) Statement on Auditing Standards (SAS) No. 69, *The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles*. With the issuance of SFAS No. 162, the GAAP hierarchy for nongovernmental entities will move from auditing literature to accounting literature. SFAS No. 162 will be effective 60 days following the SEC's approval of the Public Company Accounting Oversight Board (PCAOB) amendments to AU Section 411, *The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles*. This statement became effective during this quarter and did not have an impact on our financial position and results of operations.

In March 2008, the FASB issued SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities*, as an amendment of SFAS No. 133. SFAS No. 161 is intended to improve financial reporting about derivative instruments and hedging activities by requiring enhanced disclosures to enable investors to better understand their effects on an entity's financial position, financial performance, and cash flows. SFAS No. 161 is effective for any reporting period (annual or quarterly interim) beginning on or after November 15, 2008. We are currently evaluating the potential impact of SFAS No. 161 on our financial position and results of operations. This statement is effective for our fourth quarter interim period ending March 28, 2009 and our 2009 annual financial statements.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), *Business Combinations* (SFAS 141(R)). In SFAS 141(R), the FASB retained the fundamental requirements of SFAS No. 141 to account for all business combinations using the acquisition method (formerly the purchase method) and for an acquiring entity to be identified in all business combinations. However, the new standard requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors and other users all of the information they need to evaluate and understand the nature and financial effect of the business combination. SFAS 141(R) is effective for annual periods beginning on or after December 15, 2008. We are currently evaluating the potential impact of SFAS 141(R) on our financial position and results of operations. This statement is effective for our fiscal year 2010.

In December 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements - an amendment of ARB No. 51*, of which the objective is to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards by requiring all entities to report noncontrolling (minority) interests in subsidiaries in the same way - as equity in the consolidated financial statements. Moreover, SFAS No. 160 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. SFAS No. 160 is effective for annual periods beginning on or after December 15, 2008. We are currently evaluating the potential impact of SFAS No. 160 on our financial position and results of operations. This statement is effective for our fiscal year 2010.

**Cautionary Statement Regarding Forward-Looking Information**



## Edgar Filing: HAEMONETICS CORP - Form 10-Q

Statements contained in this report, as well as oral statements we make which are prefaced with the words may, will, expect, anticipate, continue, estimate, project, intend, designed, and similar expressions, are intended to identify forward looking statements regarding events, conditions, and financial trends that may affect our future plans of operations, business strategy, results of operations, and financial position. These statements are based on our current expectations and estimates as to prospective events and circumstances about

Table of Contents

which we can give no firm assurance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made. As it is not possible to predict every new factor that may emerge, forward-looking statements should not be relied upon as a prediction of our actual future financial condition or results. These forward-looking statements, like any forward-looking statements, involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include technological advances in the medical field, and our standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand and market acceptance of our products, regulatory requirements for the marketing of our products, government reimbursement policies and practices, regulatory requirements relating to manufacturing, sale or disposal of raw materials and finished products that contain certain chemicals, the effect of economic and political conditions, the impact of competitive products and pricing, price volatility in petroleum products (plastics are the principal component of our disposables, which are the main source of our revenues), the impact of industry consolidation, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the Plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate. The foregoing list should not be construed as exhaustive.

Table of Contents

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**



## Edgar Filing: HAEMONETICS CORP - Form 10-Q

The Company's exposures relative to market risk are due to foreign exchange risk and interest rate risk.

### **FOREIGN EXCHANGE RISK**

See the section entitled Foreign Exchange for a discussion of how foreign currency affects our business. It is our policy to minimize for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge anticipated cash flows from forecasted foreign currency denominated sales. We do not use the financial instruments for speculative or trading activities. At December 27, 2008, we had the following significant foreign exchange contracts to hedge the anticipated cash flows from forecasted foreign currency denominated sales outstanding:

Hedged Currency	(BUY) / SELL Local Currency	Weighted Spot Contract Rate	Weighted Forward Contract Rate	Fair Value	Maturity
Euro	6,700,000	\$ 1.503	\$ 1.482	\$ 583,063	Jan 2009 - Feb 2009
Euro	12,800,000	\$ 1.568	\$ 1.544	\$ 1,908,369	Mar 2009 - May 2009
Euro	11,200,000	\$ 1.489	\$ 1.464	\$ 809,051	Jun 2009 - Aug 2009
Euro	11,307,000	\$ 1.319	\$ 1.313	\$ (800,346)	Sep 2009 - Nov 2009
Japanese Yen	800,000,000	105.8 per US\$	104.1 per US\$	\$ (1,147,756)	Jan 2009 - Feb 2009
Japanese Yen	1,195,000,000	105.3 per US\$	103.3 per US\$	\$ (1,624,402)	Mar 2009 - May 2009
Japanese Yen	1,116,000,000	107.3 per US\$	105.2 per US\$	\$ (1,705,352)	Jun 2009 - Aug 2009
Japanese Yen	1,198,061,000	95.4 per US\$	94.1 per US\$	\$ (569,052)	Sep 2009 - Nov 2009
Total:				\$ (2,546,425)	

We estimate the change in the fair value of all forward contracts assuming both a 10% strengthening and weakening of the U.S. dollar relative to all other major currencies. In the event of a 10% strengthening of the U.S. dollar, the change in fair value of all forward contracts would result in a \$14.6 million increase in the fair value of the forward contracts; whereas a 10% weakening of the US dollar would result in a \$15.9 million decrease in the fair value of the forward contracts.

### **INTEREST RATE RISK**

All of our long-term debt is at fixed rates. Accordingly, a change in interest rates has an insignificant effect on our interest expense amounts. The fair value of our long-term debt, however, does change in response to interest rate movements due to its fixed rate nature. These changes reflect the premium (when market interest rates decline below the contract fixed interest rates) or discount (when market interest rates rise above the fixed interest rate) that an investor in these long term obligations would pay in the market interest rate environment.

At December 27, 2008, the fair value of our long-term debt was approximately \$0.7 million higher than the value of the debt reflected on our financial statements. This higher fair market is entirely related to the \$5.5 million remaining principal balance of the original \$10.0 million, 8.41% real estate mortgage due January, 2016.

Using scenario analysis, if the interest rate on all long-term maturities changed by 10% from the rate levels that existed at December 27, 2008, the fair value of our long-term debt would change by approximately \$0.1 million.





**Table of Contents**

**ITEM 4. CONTROLS AND PROCEDURES**



## Edgar Filing: HAEMONETICS CORP - Form 10-Q

We conducted an evaluation, as of December 27, 2008, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer (the Company's principal executive officer and principal financial officer, respectively) regarding the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15 of the Securities Exchange Act of 1934 (the Exchange Act). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.

No change in the Company's internal control over financial reporting occurred during the three months ended December 27, 2008 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents

**PART II - OTHER INFORMATION**

Item 1. Legal Proceedings

Not applicable

Item 1A. Risk Factors

In addition to the other information set forth in this report, careful consideration should be given to the factors discussed in Part 1, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 29, 2008, which could materially affect the Company's business, financial condition or future results. The risks described in the Company's Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to the Company or that it currently deems to be immaterial also may materially adversely affect its business, financial condition and/or operating results.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults upon Senior Securities

Not applicable.

Item 4. Submission of Matters to a Vote of Security Holders

None

Item 5. Other Information

None

Item 6. Exhibits

- 31.1 Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Brad Nutter, Chairman and Chief Executive Officer of the Company
- 31.2 Certification pursuant to Section 302 of Sarbanes-Oxley of 2002, of Christopher Lindop, Chief Financial Officer and Vice President Business Development of the Company
- 32.1 Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Brad Nutter, Chairman and Chief Executive Officer of the Company
- 32.2 Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Christopher Lindop, Chief Financial Officer and Vice President Business Development of the Company

Table of Contents

**SIGNATURES**





Edgar Filing: HAEMONETICS CORP - Form 10-Q

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HAEMONETICS CORPORATION

Date: February 2, 2009

By: /s/ Brad Nutter  
Brad Nutter, Chairman and Chief Executive Officer  
(Principal Executive Officer)

Date: February 2, 2009

By: /s/ Christopher Lindop  
Christopher Lindop, Chief Financial Officer and Vice  
President Business Development (Principal Financial Officer)